kronos bio ends lease early, expects cost savings

Published 05/06/2025, 12:14
kronos bio ends lease early, expects cost savings

Kronos Bio, Inc. (NASDAQ:KRON), a clinical-stage biopharmaceutical company with a market capitalization of $41 million, announced the termination of its office lease at 301 Binney Street, Cambridge, Massachusetts. The agreement with landlord BMR-Rogers Street LLC, initially set to expire on February 28, 2031, will now end on June 30, 2025. The company’s stock is currently trading near its 52-week low of $0.65.

The company will pay approximately $22.5 million to the landlord as part of the termination agreement. In return, Kronos Bio will receive a refund of a $2.0 million security deposit within 60 days post-termination. The early termination is expected to result in cost savings of approximately $18.2 million for the company.

This information is based on a recent SEC filing.

In other recent news, Kronos Bio, Inc. has announced a definitive merger agreement with Concentra Biosciences, LLC. Under the agreement, Concentra will acquire Kronos Bio for $0.57 per share in cash, alongside a non-tradeable contingent value right (CVR) per share. This merger, unanimously approved by Kronos Bio’s Board of Directors, is expected to finalize in mid-2025, contingent on customary closing conditions. These conditions include a tender offer for all outstanding shares and the availability of at least $40 million in net cash at closing. Additionally, Kronos Bio has decided to terminate its lease agreement for its headquarters in San Mateo, California, ahead of schedule. The company agreed to a $1.4 million settlement with the landlord, which accounts for a security deposit and replaces the $1.6 million in base rent due until the original lease expiration. This lease termination is a notable financial transaction, although Kronos Bio has not disclosed future plans for a new headquarters. Both developments were detailed in recent filings with the Securities and Exchange Commission.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.